Transplantation of allogeneic islets can correct the metabolic abnormalities of Type I diabetes. Limited availability of donor pancreas tissues restricts the application of this therapeutic modality to a subset of eligible recipients. In an attempt to expand the utility of available donor human pancreas tissue, we developed a method to stimulate the proliferation of insulin-secreting B-cells within human islets. A lentiviral vector was used to introduce into human islets chimeric signaling receptors that are activated to stimulate cell proliferation through interactions with a small-molecule drug called a chemical inducer of dimerization (CID). In vitro exposure of vector-transduced human islets to the CID expanded the number of cells and increased regulated insulin secretion. Transplantation of the regenerated islets into diabetic immunodeficient mice, followed by in vivo administration of the CID, corrected hyperglycemia. This strategy has the potential to reduce the quantity of human islets required for treatment of patients with Type I diabetes.
INTRODUCTION
Autoimmune destruction of islets in the pancreas leads to the development of insulin-dependent diabetes mellitus (Type I diabetes). Replacement of insulin-producing tissue by transplantation of islets, together with immune suppression, has corrected hyperglycemia in a number of patients. However, the limited availability of donor tissue and the nonproliferative status of islets ex vivo limit this approach, since pancreatic islets from at least two donors are typically necessary for each recipient [1] . A number of strategies are being pursued to increase the availability of allogeneic islets for transplantation, such as including the use of stem cells and inducing proliferation of islets [2, 3] . A proliferation switch comprising a drug-inducible chimeric receptor has been used to induce reversibly the proliferation of lineages of the hematopoietic system [4, 5] . The proliferation switch consists of a growth factor receptor signaling domain fused to binding domains for a chemical inducer of dimerization (CID). The CID used in this study is AP20187, a bivalent cell-permeant compound that binds simultaneously to two FKBP12 protein domains [6] . Addition of AP20187 to engineered cells induces dimerization of the FKBP domains fused to growth factor receptor signaling domains, which can in turn trigger cell division through signal-dependent kinase activity [7, 8] .
Incorporation of the proliferation switch in target cells such as islets can be performed with gene transfer vehicles. A number of gene transfer strategies have been evaluated for transduction of islets ex vivo [9] . Lentiviral vectors were reported to transduce islets stably with good efficiency [10] [11] [12] . We recently showed that HIV-based vectors pseudotyped with the envelope protein from the lymphocytic choriomeningitis virus (LCMV) are less toxic and transduce human islets more efficiently than the commonly used vesicular stomatitis virus G protein (VSV-G)-pseudotyped HIV vector [13] . These data also showed that LCMV-pseudotyped HIV vector transduces insulinand glucagon-positive cells (h-and a-cells) with similar efficiencies.
The present study explores the possibility of using growth switches for inducing proliferation of human pancreatic islets ex vivo and in vivo. Results show that engineered islets with a lentiviral vector encoding a growth switch could proliferate ex vivo in response to pharmacologic stimulation. Analysis of expanded islets revealed that insulin secretion was not compromised upon glucose stimulation, indicating that function was preserved. Finally, transplantation of expanded modified islets in immunocompromised diabetic mice combined with in vivo administration of the CID resulted in progressive normalization of glucose levels over time.
RESULTS

Ex Vivo Expansion of Human Islets with Two Chemically Inducible Growth Switches
We cloned two candidate cell growth switches into HIVbased vectors and concentrated LCMV-pseudotyped particles were produced. The candidate receptors were derived from the erythropoietin receptor (EpoR) and the type I fibroblast growth factor receptor (FgfR). These receptors are members of the receptor tyrosine kinase family and signal the cell to divide upon dimerization [14, 15] . EpoR is expressed by human islets and was shown to protect islets in culture from cytokine-induced apoptosis when activated [16] . Inhibition of FgfR activity in mouse pancreatic islets leads to diabetes and regression in the number of h-cells in vivo [17] . Both receptors have the capacity to signal through the JAK/ STAT pathway, which is functional in pancreatic h-cells [15, 18, 19] .
We evaluated both growth switches (FgfR-GS and EpoR-GS) in vitro following transduction of intact human islets with an LCMV-pseudotyped HIV vector expressing FgfR-GS or EpoR-GS (LCMV-HIV-FgfR-GS or EpoR-GS, respectively). We evaluated transduction efficiency of LCMV-HIV-FgfR-GS or EpoR-GS in human islets by immunodetection of FKBP12, a constituent of the chimeric receptor, which remained undetectable in untransduced control islets. An average of 46 F 3% of combined insulin-or glugacon-expressing islet cells were positive by immunofluorescence with the anti-FKBP12 antibody following transduction with LCMVpseudotyped vectors. We cultured transduced and untransduced human islets in the presence of CIDcontaining medium for 5 days, after which we established the total number of viable cells by trypan blue exclusion. Fig. 1 shows that human islets transduced with LCMV-HIV-EpoR-GS and cultured in the presence of the drug had, on average, 2.5-fold more cells (7.7 F 0.7 Â 10 5 cells) than uninduced or control untransduced islets (3.0 F 0.5 Â 10 5 and 3.1 F 0.6 Â 10 5 cells, respectively). LCMV-HIV-FgfR-GS-transduced islets showed more modest expansion compared to controls, with an average of 1.6-fold increase in the total number of viable cells (4.8 F 0.4 Â 10 5 compared to the average of 3.1 F 0.6 Â 10 5 cells for the controls). Untransduced islets cultured in the absence or presence of the CID showed comparable average numbers of total cells (3.0 F 0.6 Â 10 5 without the drug and 3.1 F 0.6 Â 10 5 with the drug), suggesting that no negative effect on the number of cells was caused by the CID itself at 10 nM (Fig. 1) . Unstimulated transduced and untransduced islets showed a similar number of total viable islets equivalent on average (e.g., 3.0 F 0.5 Â 10 5 cells for EpoR-GS without the drug and 3.1 F 0.6 Â 10 5 cells for untransduced islets), suggesting that expansion of islets requires both the expression of FgfR or EpoR and the presence of the CID.
Engineered Human Islets Conserve Functionality upon Induced Proliferation
Attempts to expand other types of differentiated epithelial cells such as hepatocytes have been associated with loss of differentiated function [20] . Therefore, we performed a number of studies to assess the function of expanded islets following amplification. We performed immunofluorescence analysis to assess whether expanded islets and unamplified controls contained comparable amounts of insulin-and glucagon-positive cells. The 5-day expansion of EpoR-GS-transduced islets resulted in a slight increase in the percentage of insulinpositive cells, but not glucagon-positive cells, compared to control untransduced islets, while no difference in the percentage of insulin-or glucagon-positive cells was observed in FgfR-GS-transduced islets (Table 1) . We measured the amount of intracellular insulin present in unexpanded and expanded islets by radioimmunoassay (RIA). EpoR-GS-expanded islets had 93 F 5 AU/ml of cell lysate, whereas control untransduced cells had 62 F 11 AU/ml of cell lysate. These data suggest that EpoR-GSstimulated islets produced elevated insulin levels upon drug induction compared to control islets. We also analyzed expanded or unexpanded islets by perifusion, a dynamic process evaluating the amount of insulin that is released from islets following exposure to changes in glucose concentration [21] . Perifusion assay revealed that islets transduced with EpoR-GS released a slightly higher amount of insulin upon glucose stimulation than control islets, whereas comparable insulin release was observed for islets transduced with FgfR-GS and untransduced control islets (Fig. 2) .
In Vivo Administration of the CID to Transplanted Diabetic Mice Leads to Normalized Glucose Levels over Time
We transplanted untransduced control or EpoR-transduced human islets, following 5 days in culture in the presence of the drug, into diabetic SCID mice (streptozotocin treated). Each mouse was transplanted under the kidney capsule with 1000, 500, or 250 islets and blood glucose levels were monitored over time. The optimal number of islets to be transplanted for obtaining full restoration of normoglycemia was established at 1000 human islets per mouse (data not shown). Transplantation of fewer islets (500 or 250) led to transient and partial reduction in glucose levels. At a dose of 500 islets, blood glucose levels decreased considerably (~200 mg/dl) following transplantation of either control or EpoR-GStreated islets. However, over a 2-week period, blood glucose levels slowly increased back to a diabetic phenotype (N300 mg/dl) for all groups, presumably because of the progressive loss of human islets due to exhaustion from an inadequate islet mass (Fig. 3A) .
We then performed transplantation experiments to address whether in vivo administration of the CID could enhance the function of the engineered transplanted islets in vivo and delay the clinical recurrence of diabetes in recipient mice. We cultured untransduced, enhanced green fluorescent protein (EGFP) control, or EpoR-GStransduced human islets for 5 days in the presence of the CID in vitro and transplanted 500 islets into individual diabetic streptozotocin-treated SCID mice, as described above. We recorded blood glucose level over time from each experimental mouse. Fig. 3B shows that early after transplantation, blood glucose levels dropped in all groups, with kinetics similar to those observed previously (see Fig. 3A ). The drug was injected to all recipient mice beginning on day 10 posttransplantation, when blood glucose levels were rising and were at or above 300 mg/dl for all groups (Fig. 3B , first arrow at day 15). Following in vivo administration of 2 mg/kg of the drug every 2 days, blood glucose levels of EpoR-GS recipient mice slowly decreased over a 21/2-month period to reach normal levels (as low as 100 mg/dl). In contrast, mice transplanted with untransduced or EGFP control islets remained diabetic, with blood glucose levels mostly above 300 mg/dl. Between day 22 and day 55, only the EpoR-GS recipient mice gained weight and stabilized at an average of 26 g per mouse (Fig. 3C ). To confirm that normalized blood glucose levels were due to transplanted EpoR-GS-modified islets, we removed the recipient kidneys at day 91 and monitored blood glucose level. Fig. 3B shows that blood glucose levels returned to 300 mg/dl shortly after kidney removal (see second arrow at day 91 
DISCUSSION
This study demonstrates the feasibility of inducing human h-cell proliferation in vitro. Importantly, the hcells retain normal differentiated function following a 2.5-fold expansion. More extensive expansion of islets in vitro will likely require further optimization of culture conditions. The suitability of these engineered and regenerated islets for transplantation was demonstrated following transplantation into diabetic mice. Long-term correction of hyperglycemia by in vivo administration of the CID in recipients of the engineered islets suggests that the interaction of the CID with the chimeric receptor either stabilizes the h-cell or stimulates its regeneration in vivo.
The results outlined in this study indicate that human islets engineered with LCMV-pseudotyped HIV-based vector encoding the EpoR-derived growth switch can   FIG. 3 . Glucose levels over time following transplantation of modified islets into diabetic SCID mice. (A and B) SCID mice were injected with streptozotocin and diabetic animals were transplanted with transduced, untransduced, or EGFP control islets 5 days later (B, star) and glucose levels were monitored over time. Ten days posttransplantation, intraperitoneal administration of 2 mg/kg AP20187 was initiated (B, first arrow at day 15) and repeated every 2 days to all transplanted mice for the length of the experiment. At day 91 (B, second arrow), the recipient kidney was removed to assess the origin of the insulin responsible for normalized glucose levels. (C) Weight of transplanted mice is shown between days 22 and 55. Kinetics represent means of 4 mice per group (A and C) or 16 mice per group receiving islets from four donors (B). Control mice died from the surgery or later during the course of the experiment and 8 total EGFP mice survived 94 days (when the experiment was ended), whereas all mock mice were dead at day 81 (C). Seven EpoR mice survived the surgery and none died during the course of the experiment. proliferate in vitro in response to drug stimulation. Twice as many diabetic SCID mice could be transplanted with expanded EpoR-GS-modified islets than with unresponsive control islets. Characterization of transduced islets also showed that expansion did not cause undifferentiation of h-and a-cells and instead resulted in increased insulin production from h-cells, probably explaining the slight increase in the percentage of insulin-positive cells by immunofluorescence. Importantly, in vivo administration of the drug lowered blood glucose to normal levels over time in recipient mice receiving EpoR-GSengineered human islets. Normoglycemia associated with an increased production of insulin from scattered transplanted EpoR-treated islets supports the hypothesis that islet expansion occurred in vivo upon drug administration. It is possible that CID-induced dimerization of the growth switch initiates activation of the Janus family kinase JAK2, which in turn activates the signal transducer and activator of transcription STAT5, leading to upregulation of transcription factors capable of stimulating cell division, as previously described for the erythropoietin receptor (for review see Refs. [22, 23] ). This promising strategy still faces important technical challenges including a more formal assessment of safety. However, scaling up transduction from 50 to 3000 islets was possible and gave encouraging results in mice, although ex vivo expansion was modest ( Fig. 1 and data not shown) . The possibility of transplanting reduced numbers of modified islets that could expand in vivo upon drug stimulation may help resolve this problem. Moreover, the possibility of inducing islet expansion in vivo in a timely manner could prove to be sufficient for overcoming natural immune destruction of islets. Indeed, a sufficient rate of proliferation could tilt the balance of the slow destruction of islets toward an overall increase in islet mass. Regulated proliferation of human islets may provide an invaluable molecular tool for the treatment of Type I and possibly Type II diabetes.
MATERIALS AND METHODS
Isolation and culture of human islets. Human pancreas organs were obtained through the local organ procurement organization. Pancreatic islets were isolated using a modification of the automated Ricordi method [24] . Briefly, collagenase (Liberase; Roche, Nutley, NJ, USA) at a concentration of 1.66 mg/ml in HanksT balanced salt solution was infused into the main pancreatic duct using a hand-held syringe and a Webster cannula. Organs were digested at 378C for 15-25 min in a Ricordi chamber that was agitated with a mechanical shaker to facilitate the digestion process. After digestion, the dispersed pancreatic tissues were washed three times with RPMI culture medium and resuspended in UW solution for 1 h. The liberated islets were then separated from exocrine tissues using the COBE 2991 (not refrigerated) and a top-loaded continuous Ficoll gradient (density range 1.055-1.120). Islet fractions with highest purity (N80-90%) were cultured in CMRL 1066 medium (Cellgro/Mediatech, VA, USA) supplemented with 10% endotoxin-free fetal calf serum (FCS; Cellgro/Mediatech) and antibiotic/antimycotic solution (Gibco BRL, Grand Island, NY, USA) in a humidified 5% CO 2 incubator at 248C, prior to in vitro and in vivo functional assessments. Human islets were cultured at 378C with 5% CO 2 in CMRL 1066 (Cellgro) supplemented with 10% FCS and 1% penicillin/streptomycin. The culture medium was replaced every day with fresh medium with or without 10 nM AP20187 for the length of the experiment (2 to 5 days). Cultured islets were transduced with EGFP or growth switch-encoding vector in a 96-or 6-well plate containing approximately 50 islets per 150 Al or 3000 islets per 5 ml of medium per well, respectively. Cultured islets were examined using fluorescence and light microscopy 5 days posttransduction.
Transplantation of human islets in mice. To evaluate function in vivo, isolated human islets were transplanted into immunodeficient diabetic mice. NOD-SCID mice were rendered diabetic by intraperitoneal injection of the h-cell toxin streptozotocin (Zanosar; Upjohn, Kalamazoo, MI, USA; two doses of 150 mg/kg on days 0 and 2). Diabetes was defined as an increased blood glucose level (N350 mg/dl) for 2 consecutive days, determined using glucose oxidase strips (Boehringer Mannheim Accu Check III). Diabetic recipients were transplanted with islets under the kidney capsule, and graft function was monitored by blood glucose measurement daily during the first month and twice weekly thereafter. Two milligrams per kilogram AP20187 was administered intraperitoneally every 2 days to control or EpoR-GS-treated mice starting 10 days posttransplantation and for the length of the experiment. At the end of the experiment (91 days posttransplantation), the kidney bearing the transplanted islet graft was removed by surgical nephrectomy and blood glucose was monitored for the next week to confirm that a functioning islet graft was responsible for the maintenance of normoglycemia.
Vector production and transduction. The previously described helper packaging construct pCMVDR8.2 encoding the HIV helper function [25] , the transfer vector pHxVEGFPWP encoding the EGFP, pHxCMVLFv2hFGFR1 or pHxCMVLFv2hEpoR encoding the fibroblast growth factor or erythropoietin receptor recombinant growth switch, respectively, and plasmids encoding envelope proteins were used for triple transfection. The transfer vector pHxVEGFPWP was generated by cloning the NheI/BamHI fragment containing the hCMV promoter and EGFP gene from pAAV2EGFP [26] and the BamHI/EcoRI fragment containing the WPRE into pHRVcPPT [25] in a three-fragment ligation. pHxCMVLFv2hE-poR expresses a fusion protein consisting of the extracellular and transmembrane domains of the human low-affinity nerve growth factor receptor, two copies of the FKBP point mutant F36V [27] , and amino acids 273-508 of the human Epo receptor. In pHxCMVLFv2hFGFR1, the human Epo receptor is replaced by amino acids 398-822 of the human FGF receptor 1. Both fusion proteins are expressed from the CMV promoter in the previously described pHx lentiviral vector [25] .
Plasmids encoding the following viral envelopes were used to generate pseudotyped viruses: pMD.G encoding the Rhabdoviridae VSV-G envelope and pHCMV-LCMV-GP [28] encoding the paramyxovirus lymphocytic choriomeningitis virus envelope proteins. Pseudotyped HIV-based vector was produced by triple transfection using the CaPO 4 precipitation method as described elsewhere [29] . Briefly, 293 T cells were transfected with the HIV packaging plasmid and the appropriate transfer and envelope expression vector and washed twice with serum-free DMEM 16 h later. Pseudotyped virus-like particles were concentrated from cell-free supernatant by ultracentrifugation 48 h posttransfection. Vector was resuspended in complete DMEM and stored at À808C. Transducing units per milliliter was determined for EGFP vector stock by looking at EGFPpositive cells using limiting dilution on 293 T cells. All experiments involving the production and functional analysis of replication-incompetent HIV-based pseudotyped vectors were performed under Biosafety Level 2+ containment, as approved by the Wistar Institute Institutional Biosafety Committee.
Transduction was performed by adding 10 Ag of Gag p24 (equivalent to 5 Â 10 7 transducing units) of pseudotyped HIV-1-based vector per 50 islets equivalent per well in a 96-well plate or 400 Ag of p24 (equivalent to 2 Â 10 9 transducing units) per 3000 islets per well in a 6-well plate. Transduction was performed by incubating 50 human islets with LCMV-pseudotyped HIV-based vector expressing FgfR-GS or EpoR-GS in a 96-well plate containing a total volume of 50 Al of complete DMEM mixed 1:1 with culture medium (CMRL 1066) for 2 h at 378C. One hundred microliters of culture medium was then added per well for 16 h. For large-scale transduction of human islets, approximately 3000 islets were centrifuged at 125g at 258C with 1 ml of concentrated pseudotyped vector for 1 h (spinoculation). Two milliliters of culture medium was then added and replaced with 5 ml of fresh medium 16 h later. Culture medium (150 Al or 5 ml) was replenished with fresh culture medium every day for the length of the experiment. Transduction efficiency was calculated as the percentage of combined insulin-or glucagon-positive cells expressing the transgene of interest from the HIV-based vector as determined by immunofluorescence microscopy (for each sample, 200 to 300 cells were analyzed).
Histology and immunocytochemistry. Five days posttransduction, islets were disaggregated with 0.25% trypsin/EDTA (Gibco, Grand Island, NY, USA) and attached to slides with a cytospin. Islets were then fixed with acetone for 3 min and incubated for 1 h with 10% goat serum as a blocking agent. Slides were incubated for 1 h with the primary antibody (guinea pig anti-insulin; Zymed, San Francisco, CA, USA; goat antiglucagon, Santa Cruz Laboratories, Santa Cruz, CA, USA) at room temperature. Slides were then washed with PBS and incubated with (1) 1:100 diluted Cy3-conjugated donkey anti-guinea pig IgG (Jackson Immunology Laboratory, West Grove, PA, USA) or (2) 1:100 diluted rhodamine rabbit anti-goat IgG (Sigma, St Louis, MO, USA). A mounting medium containing DAPI (Vector Laboratories, Burlingame, CA, USA) was used to stain nuclei. Specimens were then examined under fluorescence microscope (Nikon Microphot-FXA) for the expression of insulin. In all cases, each incubation was followed by extensive washing with PBS. Negative controls consisted of preincubation with PBS, omission of the primary antibody, and substitution of the primary antibody by an isotype-matched nonimmune control antibody. The total number of cells was estimated by counting DAPI-stained nuclei. Histology (by hematoxylin and eosin staining) and immunocytochemistry for human insulin or glucagon were also performed from 6-Am graft recipient kidney sections as described previously [30] .
Perifusion and dosage of human insulin. One hundred islets were hand counted and placed in a plastic perifusion chamber (Millipore, Bedford, MA, USA). Perifusion apparatus consisted of computer-controlled fastperformance HPLC system (Waters 625 LC System) that allowed programmable rates of flow and glucose concentration in the perifusate, a water bath (378C), and a fraction collector. The perifusate was Krebs buffer (pH 7.4) containing 2.2 mM Ca 2+ , 0.25% bovine serum albumin, and 10 mM Hepes, equilibrated with 95% O 2 and 5% CO 2 . Glucose ramp at 1 mM per minute for 50 min was applied to examine insulin release. Insulin production was evaluated from EpoR-treated islets expanded or not expanded and from EGFP and untreated control islets by RIA using a human insulin-specific RIA kit (Linco Research, St-Charles, MO, USA) as previously described [31] .
